| For: | Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148 [PMID: 30949443 DOI: 10.5306/wjco.v10.i3.136] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v10/i3/136.htm |
| Number | Citing Articles |
| 1 |
Lluvia Sugey Sosa-Quintero, Sonia Guadalupe Barreno-Rocha, Sandra Guzmán-Silahua, Grecia Guadalupe Ornelas-Ibarra, Lluvia Giselle Demis-Eliseo, Benjamín Rubio-Jurado, Arnulfo Hernán Nava-Zavala. Biomarcadores serológicos de riesgo en linfoma no Hodgkin. Salud Jalisco 2023; 10(3) doi: 10.35366/113307
|
| 2 |
Muyang Chen, Tongshan Wang, Dianzhe Tian, Chaorui Hai, Zixuan Qiu. Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer. Heliyon 2024; 10(18) doi: 10.1016/j.heliyon.2024.e37263
|
| 3 |
Tao Peng, Yangyang Sun, Zhiwei Lv, Ze Zhang, Quanxin Su, Hao Wu, Wei Zhang, Wei Yuan, Li Zuo, Li Shi, Li-Feng Zhang, Xiaoli Zhou, Yuanyuan Mi. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-020-80146-y
|
| 4 |
Ju-Pi Li, Hsien-Cheng Huang, Po-Jen Yang, Chien-Yuan Chang, Yu-Hua Chao, Thomas Chang-Yao Tsao, Hsuan Huang, Yu-Ching Hung, Ming-Ju Hsieh, Shun-Fa Yang. FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan. International Journal of Environmental Research and Public Health 2020; 17(16) doi: 10.3390/ijerph17165694
|
| 5 |
Matthew H. Brown, William S. Mendes, Yang Song, Amol C. Shetty, Matthew E. Witek, Ranee Mehra, Kyle M. Hatten, Rodney J. Taylor, Kelly F. Moyer, Jeffrey S. Wolf, Tiffani N. Tyer, Katarina J. Steacy, Caitlin Eggleston, Claudia Datnow, Daria A. Gaykalova, William F. Regine, Lei Ren, Phuoc T. Tran, Matthew J. Ferris, Jason K. Molitoris. High frequency of RB1 mutations p16 positive early stage oropharyngeal carcinoma: A genomic and transcriptomic analysis. Oral Oncology 2026; 179 doi: 10.1016/j.oraloncology.2026.108002
|
| 6 |
Hailing Lin, Hongbo Fu, Shishen Sun, Hao Yin, Jie Yuan, Jilin Liao. Patient tissue-derived FGFR4-variant and wild-type colorectal cancer organoid development and anticancer drug sensitivity testing. Heliyon 2024; 10(10) doi: 10.1016/j.heliyon.2024.e30985
|
| 7 |
Zechen Wang, Karen S. Anderson. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer. The Cancer Journal 2022; 28(5) doi: 10.1097/PPO.0000000000000615
|
| 8 |
Sinem Koc-Gunel, Amy L. Ryan, Melanie Winter, Thomas O. F. Wagner. FGFR4 p.Gly388Arg polymorphism in PBMCs of LAM patients: findings of a pilot study. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1544910
|
| 9 |
Jung Han Kim, Soo Young Jeong, Hyun Joo Jang, Sung Taek Park, Hyeong Su Kim. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.762528
|
| 10 |
Abdolkarim Moazeni-Roodi, Sahel Sarabandi, Shima Karami, Mohammad Hashemi, Saeid Ghavami. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer. Bioscience Reports 2020; 40(10) doi: 10.1042/BSR20192051
|
| 11 |
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, Siriporn C. Chattipakorn. Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges. Biochemical Pharmacology 2025; 235 doi: 10.1016/j.bcp.2025.116845
|